This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Risk Predictors for Hypnosedative-Related Complex Sleep Behaviors: A Retrospective, Cross-Sectional Pilot Study

Tzung-Jeng Hwang, MD; Hsing-Chang Ni, MD; Hsi-Chung Chen, MD; Yi-Ting Lin, MD; and Shih-Cheng Liao, MD

Published: April 20, 2010

Article Abstract

Objective: To explore the risk predictors for complex sleep-related behaviors (CSBs) in subjects with a DSM-IV-diagnosed depressive disorder, anxiety disorder, adjustment disorder, somatoform disorder, or sleep disorder taking hypnosedative drugs.

Method: One hundred twenty-five subjects using hypnosedatives were enrolled from the psychiatric outpatient clinics of a medical center in Taiwan from May 2006 to July 2006. All subjects completed a questionnaire that included demographic data, current and childhood sleep habits, and CSBs after taking hypnosedatives. Complex sleep-related behaviors were defined as somnambulism with object manipulation, sleep-related eating, and other amnestic sleep-related behaviors. Demographic and clinical variables were compared in those with CSBs and those without. Then multiple logistic regression analyses were performed in order to identify significant risk predictors for CSBs.

Results: Of the 125 subjects, 19 (15.2%) reported CSBs, all of whom took zolpidem. Among a total of 67 subjects taking zolpidem, those with CSBs were significantly more likely to be younger (P‘ ‰=‘ ‰.023), to be female (P‘ ‰=‘ ‰.011), to take a higher dose of zolpidem (>‘ ‰10 mg/d; P‘ ‰<‘ ‰.001), and to not go to sleep immediately after taking zolpidem (P‘ ‰=‘ ‰.047). Multiple logistic regression analyses showed that a higher dose of zolpidem (>‘ ‰10 mg/d) was the only significant predictor of CSBs (OR‘ ‰=‘ ‰13.1; 95% CI, 2.6-65.9; P‘ ‰=‘ ‰.002).

Conclusions: This pilot study suggests that a higher dosage of zolpidem (>‘ ‰10 mg/d) is the key risk predictor for CSBs.

J Clin Psychiatry

Submitted: January 27, 2009; accepted May 26, 2009.

Online ahead of print: April 20, 2010 (doi:10.4088/JCP.09m05083bro).

Corresponding author: Tzung-Jeng Hwang, MD, Department of Psychiatry, National Taiwan University Hospital, No. 7 Chung-Shan South Rd, Taipei 100, Taiwan (tjhwang@ntu.edu.tw).

Volume: 71

Quick Links: Neurologic and Neurocognitive , Neurology

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...